In this week’s healthcare webinar, self-insured employer leaders shared what’s actually bending the healthcare cost curve without sacrificing access or the employee experience. Across plans covering roughly 6,000 to 50,000+ lives (and up to ~$750M in annual spend), the consensus was clear: meaningful savings are coming from targeted interventions, not broad, one-size-fits-all programs.
A growing trend: the same three pressures are showing up everywhere. These are high-cost claimants, inpatient/surgical episodes, and pharmacy, with GLP‑1s emerging as a major budget shock (one employer reported GLP‑1s at 16% of Rx spend in Q1 2026).
What’s working now:
-
Centers of Excellence (COEs) for surgeries: Employers are tightening steerage by making COE use mandatory for select procedures. Particularly high-cost, high-variation episodes. One panelist shared $1M+ in savings and cost avoidance tied to COE enforcement and episode discipline.
-
More assertive GLP‑1 management: Beyond standard PBM controls, one employer carved GLP‑1s out of the PBM and paired clinical engagement requirements (nutrition/coaching) with refill eligibility, using a shared-cost model to balance affordability and access.
-
Claims integrity to stop “silent leakage:” Pre-pay review, benchmarking high-dollar claims, and coding validation are uncovering discrepancies. These often save hundreds to thousands per high value claim, as employers respond to trends like CPT code inflation. (Vendors referenced: WebTPA, SmartLight Analytics, finHealth, and Healthcare Horizons.)
-
PBM governance, not “set-and-forget:” Employers described aggressive formulary and net-cost management. One reported removing 1,000+ drugs from a PBM formulary through ongoing oversight.
-
Vendor fatigue is real: Employers are moving from optional navigation tools (due to low uptake) to embedded, required pathways. This means mandated consults for surgical requests and simpler routing through a TPA or partner.
CHRO takeaways: High-cost claimants remain the “center of gravity.” Pharmacy, especially GLP‑1s and specialty drugs, now require continuous governance. The next phase may involve more “unbundled” models to reach the lowest net cost but that would require stronger internal oversight.
As we look ahead, shifting workforce demographics (AI implementation, aging workforce, etc.) will continue to reshape benefits demand and cost trajectory.
